Allergan Seeks MAP Merger to Keep Lead in Migraine Market

Drug Industry Daily
A A
Allergan has struck a merger deal with MAP Pharmaceuticals that would give it full rights to MAP’s migraine drug Levadex, currently pending approval.

To View This Article:

Login

Subscribe To Drug Industry Daily